Features
Get A Demo
Plans
Sign Up
Login
All Federal Agencies
Help
CSOSA Pretrial Services Agency
Child
Overview
Details
Buyer Personas
Contract Opportunities
132
Forecasts
Contract Vehicles
IDV Awards
21
Contract Awards
252
Contract Subawards
6
Major Defense Programs
Grant Opportunities
Grant Programs
Grant Awards
Grant Subawards
Government Files
199
Parent Agency
CSOSA
Federal Contract Vehicles
Not listed
Popular Federal Contract Opportunities
Not listed
Popular Federal Grant Opportunities
Not listed
Popular Federal Contract Awards
Not listed
No description provided
Metrics
Founded
Not Available
Employees Range
Not Available
Number of Employees
Not Available
Estimated Annual Revenue
Not Available
EIN Number
Not Available
Fiscal Year Ends
Not Available
Parent Company
Not Available
Funding Raised
Not Available
Market Cap
Not Available
Crunchbase Handle
Not Available
Categories
Sector > Industry > Industry Group > Sub-Industry
Not listed
SIC Code
Not listed
Name
Description
Solicitation Number
Federal Agency
Type
Posted Date
(Click to sort descending)
PSA Strategic Planning 3-day Conference - Offsite for Bargaining Unit Employees
The Pretrial Services Agency (PSA) for the District of Columbia is seeking a contractor to provide a venue to host a three-day off-site strategic planning conference for its bargaining unit employees. The conference will take place on November 6-8, 2024 from 7:00 AM to 6:00 PM EST, and accommodate approximately 90 participants. Contractors must meet specific technical requirements outlined in the Statement of Work, including locating the venue within a 15-mile radius of PSA's DC office and within 0.5 miles of public transportation. Quotes are due by October 25, 2024 at 10:00 AM EST, and all questions regarding the solicitation must be submitted by October 18, 2024 at 1:00 PM EST. The solicitation will be evaluated based on the criteria detailed in Section M of the solicitation document. This is a new requirement for PSA, not an incumbent contract. The North American Industrial Classification System (NAICS) code is 611430 - Professional and Management Development Training, with a small business size standard of $10M. The place of performance is Washington, DC 20004. The solicitation does not indicate any set-aside designations, and does not provide potential award values or budget ranges.
959P0025Q0001
Pretrial Services Agency
Solicitation 1/1
10/15/24, 1:25 PM
1. Purchase of Services for Regulated Biohazard Waste Disposal
The Pretrial Services Agency is soliciting proposals for regulated biohazard waste disposal services for two of its laboratories in Washington, D.C. The contractor will be required to remove biological waste materials such as urine samples, gloves, and lab coats from the laboratories twice per week and transport them in accordance with applicable regulations. The contract will have a one year base period and four one-year option periods. Proposals are due by April 1, 2024 and the contract is to be awarded based on technical acceptability, past performance, and price. There are no set-aside designations for this requirement. The incumbent contract is held by ASI Comprehensive Waste Management under number 959P0019C0014. The contractor must remove up to 30 boxes weighing approximately 40 pounds each from the laboratories per week. Services will be performed at the Pretrial Services Agency laboratories located at 20004 Washington, D.C. for the period between June 2024 through May 2025. The primary NAICS code is 562211 and PSC code S206.
959P0024Q0002
Pretrial Services Agency
Solicitation 1/1
2/23/24, 10:24 AM
Randox Maintenance - Base Year Plus Four Option Years
Added: Jan 15, 2016 1:34 pm This is a combined synopsis/solicitation for sole source to Randox Laboratories Limited prepared in accordance with the format in FAR Subpart 12.6 as supplemented with additional information contained in this notice. This Solicitation, PSA-16-Q-0008, is issued as a Request for Quote (RFQ). Quote submissions are being requested and a written solicitation will be issued. The Pretrial Services Agency for the District of Columbia in Washington Office of Forensic Toxicology Services (OFTS) performs urine drug testing for all defendants, adult and juvenile, in pretrial status, Drug Court, offenders on Probation or Parole, parties in child protection and delinquency matters, and other tests as ordered by the courts. An extended warranty and maintenance are being bid on in this solicitation for the Randox Evidence Investigator (EI-13270). This contract is for one base year and four option years. This requirement will support additional warranty coverage and annual maintenance. This document provides information necessary to assist in the procurement of a new warranty and maintenance plan for OFTS. This contract is for one base year and four option years. This requirement will support additional warranty coverage and annual maintenance. The North American Industry Classification System (NAICS) code is 334516 and the applicable size standard is 500 employees. This procurement is sole source to Randox. This procurement is being conducted under the FAR Subpart 13.5 Simplified Acquisition Procedures, and FAR Parts 12 and 13 or some combination thereof. The Pretrial Services Agency for the District of Columbia is a federally-funded investigations and supervision agency for defendants who are released into the community while awaiting disposition of their case(s) in both the D.C. Superior Court and U.S. District Court. Pretrial Services is an independent entity within the Court Services and Offender Supervisor Agency (CSOSA).
PSA16Q0008
Pretrial Services Agency
Award Notice 1/1
1/15/16, 1:34 PM
Randox test kits (EV3977-DOA CST XX; EV-3619-Oral Fluid Array I)
Added: Jul 10, 2015 11:32 am Pursuant to the requirements of the Competition in Contracting Act (CICA) as implemented by the Federal Acquisition Regulation (FAR) Subpart 6.3 and in accordance with the requirements of FAR 6.301 and 6.303, the justification for the use of the statutory authority cited below is justified by the following facts and rationale. (1) Contracting Activity: This Justification for Other than Full and Open Competition (JOFOC) is issued by: Pretrial Services Agency for the District of ColumbiaOffice of Finance and Administration / Procurement633 Indian Avenue, NWWashington, DC 20004-2908 (2) Nature and/or description of the action being approved:This requirement is for the acquisition of the Randox Investigator analytical reagents for the detection of drugs of abuse, including Synthetic Cannabinoids and Bath Salt Designer drugs in Urine and Oral Fluid. Synthetic Cannabinoids and Bath Salts pose a serious threat to judicial monitoring and community safety. They present a daunting analytical challenge because until recently, they have been difficult to screen for. These Synthetic Cannabinoids alone are 4 - 100 times more potent than marijuana and individuals turn to using these herbal mixtures to avoid detection by standard drug test. The best method for detecting synthetic cannabinoids is liquid chromatography/tandem mass-spectrometry (LC-MS/MS). However, instrumentation cost can be as high as $500,000.00 and requires highly skilled scientists. Designing assays that detect synthetic cannabinoids is a rapidly moving target for laboratories. To avoid detection, illicit drug makers constantly change the structure of the synthetic cannabinoids used in the herbal incense market. In addition, because commercially available THC immunoassays do not cross-react with synthetic cannabinoids, laboratories usually develop their own mass spectrometry-based assays. Randox produces ELISA, a test that uses polyclonal antibodies targeted toward different chemical moieties of the aminoalkylindole cannabinoids. Reported sensitivities for the assays are <20 ng/mL or better. Preliminary data from the manufacturer shows good cross reactivity with metabolites of several synthetic cannabinoids including emerging synthetic cannabinoids such as UR-144 and XLR-11. •(3) Description of the supplies or services required to meet the agency's needs (including the estimated value): The supplies and services required to meet the Agency's needs are: Test multiple drugs assays from a single sample aliquotAdulteration check (urine)Test for basic drugs of abuseTest for UR-144 and XLR-11 as well as other DEA scheduled synthetic Cannabinoids•· Test for DEA scheduled Bath Salts•· Test multiple sample types ( oral fluid, urine, blood )•· Compatible with various oral fluid collection devices •· On-board data analysis•· Extensive QC capabilities •· Internal QC software including Levy Jennings charts •· Multi-point QC rules and auto flagging of outliers •· Connectivity LIMS integrated for convenient reporting•· Security •· Password protected for various user levels •· Full traceability of data Storage facilities •· Store up to 20,000 sample results •· Store up to 500,000 sample test results •· Retrospective Testing •· Retrieve previously unreported tested •· Flexibility •· Multi-format option for results review •· User defined reference ranges•· Fully printable reports FDA approved (4) Statutory authority permitting other than full and open competition: 41 U.S.C. 253(c)(1); FAR 6.302-1 - Only one responsible source and no other supplies or services will satisfy agency requirements. •(5) Demonstration that the contractor's unique qualifications or the nature of the acquisition requires the use of the authority cited: The core technology is the Randox biochip onto which multiple competitive immunoassays are carried out, giving results for multiple drug assays simultaneously. Competitive immunoassays are employed for the Drugs of Abuse arrays, where drug in the specimen and drug labeled with horseradish peroxidase (HRP) directly compete for anti-boding binding sites. The biochip detection system is based on a chemiluminescent signal. This is essentially the emission of light, without heat, as a result of a chemical reaction. An enzyme is used to catalyze the chemical reaction on the biochip and generate the chemiluminescent signal. Increased levels of drugs in a specimen lead to reduced binding of drug-labeled HRP, and thus, a reduction in chemiluminescent signal. The light emitted from the chemiluminescent reaction that takes place is detected and compared to that from a calibration curve using a Charge Coupled Device (CCD) Camera. This CCD Camera simultaneously records the light emission from all the discrete test sites on each biochip on the carrier.Unique imaging software on the analyzers is used to translate the light signal into an analyte concentration. The CCD Camera is made up of a collection of light sensitive diodes, which convert light into electrons to produce an electrical charge. The brighter the light that hits a single diode, the greater the electrical charge that will accumulate at that site. The degree of light emission can therefore be quantified based on the strength of the electrical signal generated. A validated biochip image is then produced, which undergoes image analysis for quantification of the signal output at each DTR. A validated calibration curve is used to determine the concentration of each analyte. This technology allows for the detection of newer forms of synthetic cannabinoids and Bath Salts. In particular, and uniquely, it detects the latest DEA banned Synthetic Cannabinoids UR-144 and XLR-11. Additionally, the Randox platform allows for multiple sample types and minimum sample volume for multiple assay analysis from a single aliquot. No order vendor utilizes this type of technology (Biochip) to perform these types of test. (6) Efforts made to ensure that offers are solicited from as many potential sources as is practicable, including whether a notice was or will be publicized as required by Subpart 5.2 and, if not, which exception under 5.202 applies: The agency shall post its intent to sole source on the FBO Portal for a minimum of 30 days.(7) Determination by the contracting officer that the anticipated cost to the Government will be fair and reasonable:The contracting officer shall use price and/or cost analysis to determine price reasonableness. (8) Description of the market research conducted (see Part 10) and the results or a statement of the reason market research was not conducted: Research shows that Randox Laboratories is the sole manufacturer and supplier of the Biochip Array Technology based Evidence Investigator analyzer. The associated reagents are exclusively manufactured by Randox and are only commercially available from Randox global. The Pretrial Services Agency's (PSA) Office of Forensic Toxicology Services (OFTS) has found official documentation certifying Randox as sole manufacturer/supplier. PSA's OFTS has also reviewed various Scientific literature: Clinical Chemistry; Journal of Forensic Toxicology, white papers, etc. PSA's OFTS has attended various Scientific meeting presentations and workshops: AAFS, SOFT, AACC, Pittcon PSA's OFTS has also conducted various in-house and industry demonstrations. (9) Other facts supporting the use of other than full and open competition: Randox appears to be able to quickly develop new assays (synthetic cannabinoids) for up and coming drugs. UR-144 and XLR-11 were brought to market relatively fast. (10) Sources that expressed, in writing, an interest in the acquisition: None at this time.(11) Actions the agency may take to remove or overcome any barriers to competition before any subsequent acquisition for the supplies or services required: None. The agency does not anticipate the need for subsequent acquisitions. Statement of Work: Randox Biochip ReagentsSECTION C. Description/ Specification/ Works Statement for Randox Biochip Reagents •1. Introduction/ Background 1.1 The Pretrial Services Agency for the District of Columbia is an independent federal agency under the Court Services and Offender Supervision Agency. Pretrial Services Agency's Office of Forensic Toxicology Services (OFTS) performs urine drug testing for all defendants, adult and juvenile, in pretrial status, Drug Court, offenders on Probation or Parole, parents charged with abuse or neglect, and other tests as ordered by the courts. The OFTS collects over 360,000 specimens per year and performs an average of 6 tests per specimen. Approximately 3.4 million tests are performed annually. The estimated monthly drug testing volume for Oral Fluid and urines for synthetic drug is approximately is 700 samples per month. Testing will be performed on instrumentation provided by the government. This document provides information necessary to assist in the procurement of a new reagent contract for the OFTS drug testing operation. 1.2 The best method for detecting synthetic cannabinoids is liquid chromatography/ tandem mass spectrometry (LC-MS/MS). However, instrumentation cost can be as high as 500,000 dollars and requires highly skilled scientist. Recently, however, Randox introduced an ELISA test that uses polyclonal antibodies targeted toward different chemical moieties of the aminoalkylindole cannabinoids. Reported sensitivities for the assays are acceptable, and preliminary data from the manufacturer shows good cross reactivity with metabolites of several synthetic cannabinoids including emerging synthetic cannabinoids such as UR-144 and XLR-11. 1.3 Designing assays that detect synthetic cannabinoids is a rapidly moving target for laboratories. To avoid detection, illicit drug makers constantly change the structure of the synthetic cannabinoids used in the herbal incense market. In addition, because commercially available THC immunoassays do not cross-react with synthetic cannabinoids, laboratories usually develop their own mass spectrometry-based assays. 1.4 The core technology is the Randox biochip onto which multiple competitive immunoassays are carried out, giving results for multiple drug assays simultaneously. Competitive immunoassays are employed for the Drugs of Abuse arrays where drug in the specimen and drug labeled with horseradish peroxidase (HRP) directly compete for anti-boding binding sites. The biochip detection system is based on a chemiluminescent signal. This is essentially the emission of light, without heat, as a result of a chemical reaction. 1.5 An enzyme is used to catalyze the chemical reaction on the biochip and generate the chemiluminescent signal. Increased levels of drugs in a specimen lead to reduced binding of drug-labeled HRP and thus a reduction in chemiluminescent signal. The light emitted from the chemiluminescent reaction that takes place is detected and compared to that from a calibration curve using a Charge Coupled Device (CCD) Camera. This CCD Camera simultaneously records the light emission from all the discrete test sites on each biochip on the carrier.1.6 Unique imaging software on the analyzers is used to translate the light signal into an analyte concentration. The CCD Camera is made up of a collection of light sensitive diodes, which convert light into electrons to produce an electrical charge. The brighter the light that hits a single diode, the greater the electrical charge that will accumulate at that site. 1.7 The degree of light emission can therefore be quantified based on the strength of the electrical signal generated. A validated biochip image is then produced, which undergoes image analysis for quantification of the signal output at each DTR. A validated calibration curve is used to determine the concentration of each analyte. 1.8 This technology allows for the detection of newer forms of synthetic cannabinoids and Bath Salts. In particular and uniquely it detects the latest DEA banned Synthetic Cannabinoids UR-144 and XLR-11. No other immunoassay company has this capability as of yet. It allows for multiple sample types and minimum sample volume for multiple assay analysis from a single aliquot. •2. Objectives 2.1 This action is for the acquisition of the Randox test kits (EV3977-DOA CST XX; EV-3619-Oral Fluid Array I) for the Randox Investigator analytical system. This system is for the detection of drugs of abuse, including Synthetic Cannabinoids and Bath Salt Designer drugs in Urine and Oral Fluid. Synthetic Cannabinoids and Bath Salts pose a serious threat to judicial monitoring and community safety. The oral fluid kits will eventually be used in- house to supplant the external reference laboratory testing. •3. Scope of Work 3.1 Under this contract the Agency expects to conduct drug testing for routine drugs of abuse as well as specialty testing for synthetic cannabinoids, synthetic cathinones (Bath Salts) and other designer drugs by using the Randox Drug of Abuse array (Biochip) system. Total cost must not exceed 60,000 dollars. •4. Period of Performance 4.1 TBD •5. Place of Performance 5.1 90 K Street N.EWashington, D.C. 20004 Reagent Requirements •2.1. Compliance with Food & Drug Administration (FDA) Requirements: Immunoassay kits are medical devices and must have clearance from Food & Drug Administration (FDA) to be marketed. The registration and listing process specified by the FDA must be followed and the manufacturer must adhere to good manufacturing process (GMP) in the manufacture of these devices. Any mandatory recalls of the kits provided under this contract and any other problems that require notification to the FDA must be resolved as required by the FDA regulations current at the time. The Contractor shall notify the Contracting Officer and Laboratory Director by Certified or overnight mail of any recall of FDA notification within two working days of the event. •2.2. Compliance with Food & Drug Administration (FDA) Requirements: Biochip kits are medical devices and must have clearance from Food & Drug Administration (FDA) to be marketed. The registration and listing process specified by the FDA must be followed and the manufacturer must adhere to good manufacturing process (GMP) in the manufacture of these devices. Any mandatory recalls of the kits provided under this contract and any other problems that require notification to the FDA must be resolved as required by the FDA regulations current at the time. The Contractor shall notify the Contracting Officer and Laboratory Director by Certified or overnight mail of any recall of FDA notification within two working •2.3. Compliance with Food & Drug Administration (FDA) Requirements: Immunoassay kits are medical devices and must have clearance from Food & Drug Administration (FDA) to be marketed. The registration and listing process specified by the FDA must be followed and the manufacturer must adhere to good manufacturing process (GMP) in the manufacture of these devices. Any mandatory recalls of the kits provided under this contract and any other problems that require notification to the FDA must be resolved as required by the FDA regulations current at the time. The Contractor shall notify the Contracting Officer and Laboratory Director by Certified or overnight mail of any recall of FDA notification within two working days of the event. •2.4. Except as provided herein, the reagent supplied throughout the term of this contract shall be identical to the reagent offered by the contractor and accepted by the Government at the time of the contract award. If, during the course of this contract, the manufacturer wishes to change or improve its reagents, that product modification must be proposed in writing to the Contracting Officer and Laboratory Director for approval prior to its incorporation into the kits to be delivered. The contractor's proposal must include documentation, which demonstrates that the manufacturer has complied with all applicable FDA regulations, including those concerning the filing of a new 510k notice if such action and subsequent FDA clearance are warranted by the nature of the modification. Any re­validation of the modified reagent will be done by the Contractor, at their expense and at a time acceptable to the OFTS•2.5. Reagents must be compatible with the equipment provided by the Government in 5.1. The materials provided must be in volumes and packaging, which are convenient and applicable to the throughput of the OFTS and should not result in the loss or unnecessary disposal of more than 5% of the working volume of reagent. Any individual bottle of reagent, which would be prepared for use at one time, may not include materials for more than 54 tests per kit. •2.6. The reagents must be provided with a product package insert that compiles with all requirements of the FDA and includes data demonstrating specific performance characteristics, such as, accuracy, precision, sensitivity, specificity, cross-reactivity, and safety precautions. The instruction sheet(s) shall include protocols optimized for OFTS operations as represented in these specifications and at cutoffs utilized by the OFTS. The instruction sheet shall include operating parameters and instrumentation settings for use of the reagent on the Contractor's equipment •2.7. The shelf life of any unopened assay kit or component shall be at least 180 days from the date of delivery to OFTS. Once kit container seals are broken and the component opened the shelf life must be at least 30 days. •2.8. Reagents must meet current Substance Abuse & Mental Health Services Administration (SAMSHA), PSA, Department of Transportation (DOT) and Department of Defense (DOD) Standard Drug Testing Panel and Criteria for Reporting Drug Use. •2.9. Salient characteristics for Calibrators and Controls •2.9.1. The Contractor shall provide sufficient calibrator materials for the reagents which must meet the SAMSHA, PSA, DOT, and DOD cutoff at no additional charge to the Government to perform the volume of testing shown. •2. •2.7. •2.8. •2.9. •2.9.2. The Contractor shall provide sufficient control materials for the reagents at approximately 75 and 125 percent of the 25 ng/ml cutoff concentration at no additional charge to the Government to perform the volume of testing shown. •2.9.3. Calibrators and control materials must be available in not less than 5 ml or greater than 25 ml sizes (liquid). •2.9.4. Calibrators and control materials must be available in liquid form whenever available. •2.9.5. Lot numbers must be good for six months from date of receipt. •2.9.6. Calibrators and control materials must have a 30 day expiration of opened or reconstituted products. •2.9.7. Sample types include Blood, Oral Fluid and Urine matrix •2.10. Assay specific requirements •2.10.2. The sensitivity and specificity of the assay should provide sufficient reactivity such that an actual human physiological specimen which contains the cutoff value of a given assay is correlated by GCMS to match the apparent concentration by the immunoassay procedure. •2.10.3. The reagent must provide equivalent or better performance characteristics for the detection of drugs in human urine as the current immunoassay procedure used by OFTS. •2.10.4. The reagent must use a semi-quantitative protocol and demonstrate linearity. •2.10.5. The reagent must be specific for each individual drug assay such that no less than 95% of actual human physiological specimens identified as positive by the current OFTS immunoassay procedure will be identified as positive by the Contractor's reagent. •2.10.6. The reagent must not have more than a 5% false negative rate for actual human physiological specimens identified as positive by the current OFTS immunoassay procedure. •2.10.7. The reagent must not have more than a 5% false positive rate for actual human physiological specimens identified as negative by the current OFTS immunoassay procedure. •2.10.8. Chemical compounds that may reasonably be found in urine resulting from prescription or non-prescription drug use must be tested to characterize antibody specificity. Also, specificity testing will include biochemical materials produced normally in the human body (this may be evaluated by testing numbers of specimens of normal human urine). •2.10.9. Quality Control (QC): the individual test reagents must also maintain reproducibility in QC measurements. The testing reagent must identify as positive 95% or all QC specimens containing the drug at a concentration 125% of the OFTS cutoffs. The assay shall identify as negative by the initial test 95% of the quality control specimens that contain the designated compound at 75% of the OFTS cutoff concentration. •3. Other Requirements •3.1. The Contractor shall supply technical support. Technical support shall be provided in trouble-shooting, method set-up, and method validation. This technical support shall be available by telephone during regular business hours per day, 5 days per week by local or toll-free number at no additional cost to the government. •3.2. The Contractor if needed shall set-up and validates the initial performance of the assay on the equipment provided by the government according to current standards of practice for forensic toxicology laboratories. The Contractor shall provide documentation of these validation studies. •4. Ordering and Delivery of Materials •4.1. The Government agrees to purchase exclusively from the Contractor on a requirements basis all drug testing reagents for the testing of drugs in oral fluid and urine by the OFTS so long as the Contractor is able to meet the re-supply response times shown in 4.3 and other performance standards shown in this statement of work. •4.2. Orders for reagents, calibrators, and control materials shall be placed by the PSA contracting officer or designee. •4.3. The Contractor must be able to deliver, within 48 hours of receipt of an order, reagents, calibrators, and controls for the testing at no additional charge to the government for emergency orders and 72 hours for non-emergency orders. •5. Supporting Information •5.1. The government shall provide appropriate instrumentation for the analysis. Currently the Government uses Randox Investigator clinical chemistry analyzer. •5.2. The government will provide adequate storage facilities for reagents, calibrators, and controls. •5.3. Qualified Government operators shall perform all testing. •6. Deliverables 6.1 The contractor must provide the following items as needed for drug analysis. These include Drugs of Abuse Array I Oral Fluids (EV3619); Drugs of Abuse Array I Oral Fluid Control (EV3649); Drugs of Abuse Array V Urine (EV3977/DOA CST XX) and Drugs of Abuse Array V Urine Controls (EV3978/DOA CST XX). •7. Other Requirements 7.1. The contractor should be able to make customized changes to the Drugs of Abuse kit profiles when requested to accommodate changing drug use pattern. These changes should be at a minimum cost to the Government.
Pretrial Services Agency
Award Notice 1/1
7/10/15, 11:32 AM
Human Services for Substance Abuse Treatment Training
Added: May 13, 2010 4:28 pm District of Columbia Pretrial Services AgencyHuman Services for Substance Abuse Treatment TrainingSources Sought/SynopsisThe District of Columbia Pretrial Services Agency (PSA), a federal agency, has a requirement to obtain services for training support for 25 Pretrial Service Officers/employees in Human Services for Substance Abuse Treatment. PSA is an independent Federal agency within the Court Services and Offender Supervision Agency (CSOSA) in the Executive Branch of the Federal government. PSA's mission is to assess, supervise and provide services for defendants, and collaborate with the justice community to assist the courts in making pretrial release decisions. The training should assist government employees in acquiring the skills needed to work with substance dependant defendants and provide employees with substance abuse credit hours needed for certification exams and re-certification of PSA's current certified or licensed substance abuse professionals. This particular training should teach employees on human development and how it is impacted by addiction and recovery. All companies interested who can provide this type of training should respond electronically and provide a summary of experience and expertise in this area. A copy of training outlines and a list of references should be submitted electronically to the point of contact; Rachel Dobbs @ Rachel.dobbs@psa.gov by the close of business May 21, 2010.This is a 100% small business set-aside. The NAICS code for this requirement is 611430 and the small business size is $7.0M.
20101845SS
Pretrial Services Agency
Pre-Solicitation 1/1
5/13/10, 4:28 PM
Name
Description
Awardee
Potential Value
(Click to sort descending)
Award Date
(Click to sort descending)
Last Date To Order
(Click to sort descending)
Updated At
(Click to sort descending)
GS00F010CA-959P0023A0007
Pretrial Services Agency (CSOSA), an independent federal agency, awarded a single-award Blanket Purchase Agreement (BPA) to ICF Incorporated, L.L.C. to provide enterprise rebranding and strategic communication services. The BPA, valued up to $615,561.98, is a three-year contract with a period of performance through September 2026. Under this agreement, ICF will leverage its expertise as a global consulting and technology services provider to assist CSOSA in refining its public image and messaging strategies. The initial task order, valued at $206,068, is a firm fixed price call for rebranding and communications support. No subcontractors or set-aside designations were identified. This BPA award allows CSOSA ongoing access to ICF's capabilities in areas such as strategic communications, program management, and public outreach in support of the agency's mission.
ICF Incorporated, L.L.C.
$615.6k
9/30/23
9/30/26
2/28/24
47QRAA18D00FJ-959P0020A0006
This Blanket Purchase Agreement (BPA) was awarded by the Court Services and Offender Supervision Agency (CSOSA) Pretrial Services Agency, a civilian federal agency, to Acquisition Professionals LLC, a certified economically disadvantaged woman-owned small business (EDWOSB) and 8(a) program participant. The $150,000 BPA provides staffing services to support the Office of Finance and Administration within CSOSA. This single-award IDV was established under the General Services Administration (GSA) Multiple Award Schedule (MAS) for Professional Services. The BPA has an ultimate completion date of April 19, 2025 and was awarded on April 21, 2020. Acquisition Professionals LLC holds several other IDV contracts with federal agencies, including a $4 million single-award IDC with the USDA Rural Housing Service and a $500,000 single-award IDC with the FDA, in addition to a position on the GSA OASIS+ WOSB IDIQ. Through these various IDVs, the company provides a wide range of acquisition support, program management, and technical writing services to its government clients.
Acquisition Professionals LLC
$150.0k
4/21/20
4/19/25
4/21/20
959P0020A0010
The Pretrial Services Agency awarded a single-award blanket purchase agreement to Zuckerman Gravely Management, Inc. to provide weekly electrostatic spraying services and chlorinated tablets for disinfection at its facility located at 601 Indiana Avenue NW in Washington, D.C. Valued at $98,244.56 over its period of performance through January 31, 2023, the BPA enables the issuance of firm-fixed price call orders such as one for $15,264 to conduct electrostatic spraying at the facility through January 2021. No set-aside designation was applied. The original pre-solicitation notice indicated the Agency's intent to negotiate with Zuckerman Gravely, the property management company for 601 Indiana Avenue, to obtain the required sanitation services for its offices located at that address, in support of the Agency's mission to promote pretrial justice and community safety. The Pretrial Services Agency issued a task order against the blanket purchase agreement to Zuckerman Gravely Management, Inc. for electrostatic spraying services at its 601 Indiana Avenue facility in Washington, D.C., valued at $15,264 to be completed by January 31, 2021. The single-award BPA, with a potential value of $98,244.56 over its period of performance through January 2023, enables the Agency to issue additional firm-fixed price call orders for sanitation services from the contractor as needed to support the health and safety of Agency personnel as they fulfill their pretrial justice and community safety mission.
Zuckerman Gravely Management, Inc.
$98.2k
9/18/20
1/31/23
9/15/20
PSA16A0012
ONSITE TRAINING FOR CSRS AND FERS
Atlantic Management Center, Inc.
$36.1k
10/1/16
9/30/19
8/16/17
47QSMA23D08QL-959P0024A0001
The Blanket Purchase Agreement (BPA) was awarded by the Pretrial Services Agency to District Moving Companies, Inc., a for-profit subchapter S corporation, to provide moving and storage services. The single-award BPA has a potential value of $250,000 and a period of performance from March 18, 2024 to March 17, 2029. Under this BPA, District Moving Companies will provide relocation services such as packing, transporting, and unpacking office furnishings and equipment, as well as reconfiguring agency spaces for the Pretrial Services Agency. The company has prior experience providing similar services to federal agencies including the Department of the Navy, Department of Defense, Department of the Interior, Social Security Administration, and Environmental Protection Agency, either through firm fixed price contracts or GSA schedule task orders. District Moving Companies also holds several IDIQ and FSS contracts with potential values up to $196,650 and $475,000 respectively to provide nationwide office relocation and reconfiguration services to federal agencies.
District Moving Companies, Inc.
$250.0k
3/18/24
3/17/29
3/14/24
Name
Description
Awardee
Potential Value
(Click to sort descending)
Award Date
(Click to sort descending)
Completion Date
(Click to sort descending)
Updated At
(Click to sort descending)
Delivery Order GS07F0092W-PSA16F0109
AGILENT - NEW 7890B SERIES GCMS INSTRUMENT.
All Business Machines, Inc.
$143.2k
9/28/16
9/27/17
9/28/16
Delivery Order NNG15SD53B-959P0023F0022
This is a $1,593,655.11 firm fixed-price delivery order awarded to SHI International Corp under the Solutions for Enterprise Wide Procurement (SEWP) V government-wide acquisition contract (GWAC). The order is for the renewal of Microsoft 365 G5 Enterprise Agreement (EA) licenses, including Azure prepayment, to support the mission of the Court Services and Offender Supervision Agency (CSOSA) Pretrial Services Agency, a civilian federal agency. The award does not have a set-aside designation. SHI International Corp is a minority-owned, woman-owned, Asian-Pacific American-owned, for-profit subchapter S corporation that has received numerous prime and subcontract awards to provide IT hardware, software, and services to various federal agencies. The contract has an ultimate completion date of August 31, 2026.
SHI International Corp
$1.6m
9/1/23
8/31/25
9/27/24
Delivery Order GS25F0046M-959P0018F0080
PREMISYSID PRO CLIENT SYSTEM BY IDENTICARD FOR OHCM
Precision Dynamics Corporation
$5.1k
9/13/18
9/20/21
9/27/23
Delivery Order 959P0020D0004-959P0020F0045
The Pretrial Services Agency awarded a $206,868 firm fixed price delivery order contract to The Salvation Army for intensive outpatient treatment, residential treatment, and transitional housing services. As the prime contractor, The Salvation Army will deliver the requested behavioral health products and services to support the Agency's pretrial defendant supervision programs. No set-aside provision was applied to this award issued by the PSA in Washington, DC on September 30, 2020, with a completion date of September 29, 2021. The Salvation Army, operating as its Salvation Army name, will perform as the prime contractor for these behavioral health services for pretrial defendants.
The Salvation Army
$206.9k
9/30/20
9/29/21
9/30/20
Delivery Order GS07F0191N-PSA17F0070
TECHNICAL WRITER FOR OPERATIONS MANUAL
Hawley-Thomas Enterprises Inc.
$46.2k
9/20/17
9/30/18
9/25/23
Contract Number
Description
Subcontractor
Prime Award
Dollars Obligated
(Click to sort descending)
Updated At
(Click to sort ascending)
TO2CO1S
Salesforce support
Delaney Advantage Technologies L.L.C.
BPA Call GS00Q16AEA1001-959P0019F0080
($42k)
6/15/21
PSAWO1S
Salesforce support
Delaney Advantage Technologies L.L.C.
BPA Call GS00Q16AEA1001-959P0019F0080
$41.8k
6/15/21
TO25S
Salesforce Support
Gridiron It Solutions LLC
BPA Call GS00Q16AEA1001-959P0019F0080
$86.4k
10/16/20
TO23S
Salesforce Support
Delaney Advantage Technologies L.L.C.
BPA Call GS00Q16AEA1001-959P0019F0080
$186.2k
9/16/20
6THATTACHMENTAS
Salesforce Support
Archima LLC
BPA Call GS00Q16AEA1001-959P0019F0080
$200.7k
12/10/19